Boston-based life sciences VC firm Cure Ventures closed its debut fund with $350M in capital commitments from limited partners.
The firm has a three-step investment thesis
consisting of making smaller seed-stage bets, embedding Cure management
as C-suite executives in portfolio companies, and prioritizing genetic
validation to increase clinical success.
- Cure Ventures intends to make around 20 seed-stage bets, of which between 12 and 15 will receive Series A funding later.
- Richard Lim, David Fallace, and Lou Tartaglia establish the firm.
- The trio previously worked with Polaris and Third Rock Ventures.
- So far this year, VCs have invested $4.1B in biotech and pharmaceutical startups across 208 deals.
- VCs invested $39.3B and $32.1B in the sector in 2021 and 2022, respectively.
